Structural assessment of HLA-A2-restricted SARS-CoV-2 spike epitopes recognized by public and private T-cell receptors
Daichao Wu,
Alexander Kolesnikov,
Rui Yin,
Johnathan D. Guest,
Ragul Gowthaman,
Anton Shmelev,
Yana Serdyuk,
Dmitry V. Dianov,
Grigory A. Efimov,
Brian G. Pierce () and
Roy A. Mariuzza ()
Additional contact information
Daichao Wu: University of Maryland Institute for Bioscience and Biotechnology Research
Alexander Kolesnikov: University of Maryland Institute for Bioscience and Biotechnology Research
Rui Yin: University of Maryland Institute for Bioscience and Biotechnology Research
Johnathan D. Guest: University of Maryland Institute for Bioscience and Biotechnology Research
Ragul Gowthaman: University of Maryland Institute for Bioscience and Biotechnology Research
Anton Shmelev: National Research Center for Hematology
Yana Serdyuk: National Research Center for Hematology
Dmitry V. Dianov: National Research Center for Hematology
Grigory A. Efimov: National Research Center for Hematology
Brian G. Pierce: University of Maryland Institute for Bioscience and Biotechnology Research
Roy A. Mariuzza: University of Maryland Institute for Bioscience and Biotechnology Research
Nature Communications, 2022, vol. 13, issue 1, 1-14
Abstract:
Abstract T cells play a vital role in combatting SARS-CoV-2 and forming long-term memory responses. Whereas extensive structural information is available on neutralizing antibodies against SARS-CoV-2, such information on SARS-CoV-2-specific T-cell receptors (TCRs) bound to their peptide–MHC targets is lacking. Here we determine the structures of a public and a private TCR from COVID-19 convalescent patients in complex with HLA-A2 and two SARS-CoV-2 spike protein epitopes (YLQ and RLQ). The structures reveal the basis for selection of particular TRAV and TRBV germline genes by the public but not the private TCR, and for the ability of the TCRs to recognize natural variants of RLQ but not YLQ. Neither TCR recognizes homologous epitopes from human seasonal coronaviruses. By elucidating the mechanism for TCR recognition of an immunodominant yet variable epitope (YLQ) and a conserved but less commonly targeted epitope (RLQ), this study can inform prospective efforts to design vaccines to elicit pan-coronavirus immunity.
Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)
Downloads: (external link)
https://www.nature.com/articles/s41467-021-27669-8 Abstract (text/html)
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-021-27669-8
Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/
DOI: 10.1038/s41467-021-27669-8
Access Statistics for this article
Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie
More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().